Skip to main content
. 2021 Jun 2;12:690207. doi: 10.3389/fimmu.2021.690207

Figure 1.

Figure 1

Effects of entinostat on MDSCs. Entinostat inhibits the VEGF, ErbB and mTOR pathways in PMN-MDSCs, thereby inhibiting the activity of STAT3, which in turn reduces the activities of Arg-1, iNOS and COX2. Entinostat therapy inhibits the transport of M-MDSCs from bone marrow to the tumor environment by downregulating CCR2 expression.